trending Market Intelligence /marketintelligence/en/news-insights/trending/53LtkCcUowW0n59TNYf-Xg2 content esgSubNav
In This List

Mylan gets US FDA approval for 1st generic of Allergan's Estrace Cream

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Blog

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises


Mylan gets US FDA approval for 1st generic of Allergan's Estrace Cream

Mylan NV launched its Estradiol vaginal cream 0.01% in the U.S. after final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for the product to treat vulvar and vaginal atrophy.

Estradiol vaginal cream 0.01% is the first generic version of Allergan plc's Estrace Cream.

Estradiol vaginal cream 0.01% had U.S. sales of about $449 million for the 12 months ending Oct. 31, according to IQVIA.